Results 41 to 50 of about 6,386 (141)

Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet

open access: yes, 2007
International audiencePhenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to foscarnet.
F. Petit   +9 more
core   +1 more source

Foscarnet-Resistant Cytomegalovirus Esophagitis with Stricturing

open access: yes, 2013
We report the case of a 52-year-old man with HIV-AIDS, non-complaint with highly active antiretroviral therapy, who presented with long-standing dysphagia.
Usman Khan   +4 more
core   +1 more source

Foscarnet Decreases Human Immunodeficiency Virus RNA

open access: yes, 2017
Foscarnet inhibits human immunodeficiency virus (HIV) replication in vitro and decreases p24 antigenemia in patients with cytomegalovirus (CMV) retinitis.
Kaiser, Laurent   +6 more
core  

Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS

open access: yes, 1991
Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring \u3e6 μmol of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy.
P. V. Whitmore   +13 more
core   +1 more source

Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants [PDF]

open access: yes, 2018
We studied 97 patients who developed cytomegalovirus (CMV) viremia following an allogeneic hemopoietic stem cell transplant (HSCT) between 2010 and 2015, treated with foscarnet, with the aim of assessing efficacy and safety. The donor was unrelated in 30
Laurenti L.   +4 more
core   +1 more source

Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient

open access: yes, 2012
We present the case of a lung transplant recipient with disseminated crystal precipitation, and granulomatous and fibrinous inflammation after therapy with foscarnet (Foscavir; AstraZeneca, Zug, Switzerland) for recurring ganciclovir-resistant ...
Schuurmans, Macé M   +3 more
core   +1 more source

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

open access: yes, 2002
The present study compared foscarnet with ganciclovir for preemptive therapy of cytomegalovirus (CMV) infection after allogeneic blood or marrow stem cell transplantation (SCT). Patients with CMV infection, as detected by weekly antigenemia or polymerase
Reusser, P   +9 more
core   +1 more source

Concurrent Use of Ganciclovir and Foscarnet to Treat Cytomegalovirus Infection in AIDS Patients

open access: yes, 1993
Ten patients with AIDS and progressive cytomegalovirus disease were treated with ganciclovir and foscarnet concurrently. The patients had received ganciclovir and foscarnet monotherapy a median of 330 days before receiving combination therapy for a ...
Dieterich, Douglas T   +17 more
core   +1 more source

Home - About - Disclaimer - Privacy